Innovative Medicines Canada and Roche Canada Announce Scholarship for the University of Toronto’s Dalla Lana School of Public Health

OTTAWA, ON – (Newsfile Corp. – November 23, 2021) – Innovative Pharmaceutical Canada (IMC) and Hoffmann-La Roche Limited (Roche Canada) today announced a $50,000 scholarship in artificial intelligence and population health for the Dalla Lana School of Public Health (DLSPH) at the University of Toronto. IMC initially pledged $25,000 to celebrate the tenure of outgoing IMC Board Chair and Roche Canada’s President and CEO, Ronnie Miller, who served for two years from 2019 to 2021. Roche Canada made a similar pledge of $25,000.

The scholarship will extend over a five-year period beginning in fall 2022. It will be awarded to a graduate student at the master’s or doctoral level who is developing research and training in artificial intelligence, machine learning, and data science to improve population health and health system performance. The DLSPH grant will assist innovation in creating population health solutions and will support the next generation of public health leaders in creating transformative change.

Founded in 1926, Dalla Lana School of Public Health is world-renowned for its programs and experts. A community of scholars, educators, students, practitioners, policy makers and citizens is creating new knowledge and advanced practice and guiding the way to better and more equitable health outcomes in Canada and around the world.

Roche Canada is at the fore in innovative advances in artificial intelligence for healthcare reform. In 2020, the company launched a Center of Excellence in Artificial Intelligence called AI with Roche (AIR), which brings together the expertise of three national AI organizations: Amii, Mila, and Vector Institute. AIR is a collaborative effort that creates artificial intelligence-based solutions to improve and reduce the cost of healthcare delivery, improve health outcomes, and enable Canada to respond effectively to opportunities and challenges in the healthcare system.


“Throughout the COVID-19 pandemic, we have engaged with the AI ​​community and seen the power and potential of AI and data science to address global and local health challenges. AI and machine learning will continue to dictate a more efficient future, a more connected and better equipped healthcare system. Roche is proud to support the next generation from artificial intelligence and machine learning experts from the Dalla Lana School of Public Health as they create increasingly innovative solutions that advance the health of populations.” Ronnie Miller, IMC’s outgoing chairman.

“The past two years have seen unprecedented challenges in public health. As we continue to work through the pandemic, it is the interest, progress, and research from member companies like Roche Canada that will prepare us for the future. Growing adoption of artificial intelligence and machine learning is driving exciting solutions that increase accuracy, versatility, and ensure More patient-centered healthcare experiences. This scholarship will help the Dalla Lana School of Public Health support ground-breaking developments and future global leaders in artificial intelligence and population health for years to come.” Pamela Fralick, President of Innovative Pharma Canada.

“Collaboration and partnerships are essential to accelerate discovery for the benefit of the public health sector. My heartfelt thanks go to IMC and Roche Canada for this generous contribution to the Dalla Lana School of Public Health. Artificial intelligence and machine learning are vital tools to support and improve the efficiency of care delivery, access to health care, and patient outcomes. This grant will enable our school to continue improving our impact on public health and health systems in Canada and around the world.” Adalsteinn (Steini) Brown, professor and dean at the Dalla Lana School of Public Health.

About Innovative Medicines in Canada

Innovative Medicines Canada is a national association that represents the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development and delivery of innovative drugs and vaccines to improve the lives of all Canadians and supports members’ commitment to being a valued partner in the Canadian health care system. “The association represents 48 companies that invest approximately $1.2 billion in research and development annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to the Canadian economy. Guided by the Code of Ethical Practice, all members work with governments, private drivers and sponsors Health professionals and stakeholders in a highly ethical manner.

About Roche Canada

Roche is a leading global pharmaceutical and diagnostics company focused on advancing science to improve people’s lives. The combined strengths of drugs and diagnostics, as well as growing capabilities in data-driven medical insights, help Roche deliver truly personalized healthcare. Founded in 1931, Roche Canada employs more than 1,800 people nationwide through its Pharmaceutical Division in Mississauga, Ontario, as well as its Diagnostic and Diabetes Care divisions in Laval, Quebec.

To view an improved version of this graphic, please visit:

– 30 –

for further information:

Erin Brophy
Executive Director of Communications
Tel: 343-998-5030

To view the source version of this press release, please visit

Latest articles

Related articles

Leave a reply

Please enter your comment!
Please enter your name here